, p53 (Sidransky et al., 1991; Fujimoto et al., 1992), retinoblastoma (Rb; Horowitz et al., 1990; Cairns et al., 1991; CordonCardo et al., 1992; Logothetis et al., 1992) , c-erbB-2 (Wright et al., 1990 (Wright et al., , 1991 Coombs et al., 1991; Moriyama et al., 1991; Wood et al., 1991; Sauter et al., 1993) , epidermal growth factor receptor (EGFR; Neal et al., 1985 Neal et al., , 1990 , c-src (Fanning et al., 1992) , MDM2 (Habuchi et al., 1994; Lianes et al., 1994) and MTS1 (Cairns et al., 1994; Kamb et al., 1994; Spruck et al., 1994) .
The hypothesis that neoplastic transformation results from an accumulation of genetic alterations in a cell over time is accepted as the molecular framework underlying neoplastic progression. A significant number of genetic alterations have been demonstrated in urothelial neoplasia, including H-ras (Fujita et al., 1985; Visvanathan et al., 1988; Czerniak et al., 1990; Knowles and Williamson, 1993 ; Levesque et al., 1993) , p53 (Sidransky et al., 1991; Fujimoto et al., 1992) , retinoblastoma (Rb; Horowitz et al., 1990; Cairns et al., 1991; CordonCardo et al., 1992; Logothetis et al., 1992) , c-erbB-2 (Wright et al., 1990 (Wright et al., , 1991 Coombs et al., 1991; Moriyama et al., 1991; Wood et al., 1991; Sauter et al., 1993) , epidermal growth factor receptor (EGFR; Neal et al., 1985 Neal et al., , 1990 , c-src (Fanning et al., 1992) , MDM2 (Habuchi et al., 1994; Lianes et al., 1994) and MTS1 (Cairns et al., 1994; Kamb et al., 1994; Spruck et al., 1994) .
It has become clear that a series of diverse genetic changes are involved in generating the different phenotypes observed in bladder cancer. However, how these different genetic elements interact with other cellular proteins and complement each other in neoplastic progression is little understood. To address these issues, investigators have developed both in vitro and in vivo models of progression, including the use of human carcinoma derived cell lines. Such cell lines have been used as a resource to identify the involvement of change at a particular locus in specific tissues (Der et al., 1982; Parada et al., 1982; Horowitz et al., 1990; Fanning et al., 1992) and in studies directed at identifying the function of a gene following restoration of expression (Takahashi et al., 1991; Goodrich et al., 1992) . It is argued that changes found in cell lines are not always a reflection of events in vivo; however, molecular events associated with H-ras, Rb and c-src (Der et al., 1982; Horowitz et al., 1990; Fanning et al., 1992, respec- tively) were first identified in a panel of bladder cell lines and later confirmed to be altered in bladder tumour tissue. In this study we 
Materials and methds
Cell lines 5637, CUBIII, EJ, HT1376, HU456, J82, KK47, PSI, RT4, RT112, TCCSUP, UM-UC-3, HT1197, SCaBER (ATCC) and BC16 (kindly provided by Dr C Remikoff, University of Wisconsin) cell lines were maintained in Dulbecco's modified medium supplemented with 7.5% fetal bovine serum and penicillin/streptomycin. Immunoprecipitation MDM2 Subconfluent cells were washed in phosphatebuffered saline (PBS), lysed in ice-cold PBSTDS lysis buffer (PBS pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 100 U ml-aprotinin) for 20 min and clarified by centrifuging at 14 000 g for 20 min at 4'C. Protein for the immunoprecipitations was standardised using the BCA method (Pierce, Rockford, IL, USA) and incubated overnight at 4°C with 15 jil of anti-MDM2 (Ab-1; Oncogene Science, Manhasset, NY, USA) followed by the addition of protein A-Sepharose beads for an additional 90 min incubation at 4°C. Immunocomplexes were washed three times in PBSTDS and once in 0.1% PBS. Samples were run on a 7.5% polyacrylamide gel and proteins were transferred to nitrocellulose. Blots were blocked overnight at 4°C in 10% non-fat dried milk in triethanolamine-buffered saline (TBS) with 0.05% followed by incubation with MDM2 (Ab-1; Oncogene Science) for 2 h at room temperature. The blots were washed three times with TBST followed by incubation with a horseradish peroxidasecoupled second antibody. After additional washes in TBST, blots were developed using an ECL Kit (Amersham, Arlington Heights, IL, USA). (Table I) . Three p53 point mutations were found in one cell line, J82, two in exon 8 and one in exon 9. Transversion and transition mutation events were equally represented within this group. intensity and migrational properties in SDS-polyacrylamide gel electrophoresis (Figure 3 cells in the absence of detectable mutational change (Table   I ).
Loss of expression of the Rb gene product has been identified as a late-stage event in urothelial neoplastic progression associated with the invasive phenotype. The status of Rb in bladder carcinoma cell lines has previously been addressed, noting both loss and mutation of Rb protein product (Horowitz et al., 1989 (Horowitz et al., , 1990 . Extension of this observation to include additional bladder cell lines confirmed loss of Rb expression associated with TCCSUP, SCaBER, HT1376 and 5637, and aberrant migration of Rb in cell line J82 following immunoprecipitation (data not shown). No additional gross changes were recorded in Rb using immunoprecipitation or Western blot analysis (Table I ).
E-cadherin/catenin complex
Recent publications have indicated loss or reduction of Ecadherin expression associated with late-stage bladder tumours (Bringuier et al., 1993) . To establish the status of E-cadherin expression and associated catenins in bladder cell lines, we employed a number of different experimental approaches. Figure 5a shows (Bringuier et al.. 1993) . In the present study, loss of E-cadherin protein was observed in 5 of 15 bladder cell lines (33%) in which absence of E-cadherin message was established using RT-PCR. The molecular events leading to this loss of expression are presently uncharacterised, but it is interesting to note that BC16, a cell line immortalised by SV40. shows marked reduction of E-cadherin expression levels.
Expression of E-cadherin is not synonymous with functionality. and loss of x-catenin in the precipitated E-cadherin complex can contribute to the absence of calcium-dependent aggregation (Breen et al., 1993) . Lack of detectable a-catenin in CUBIII E-cadherin complexes was found in the presence of cx-catenin message and may be attributable to a mutation at this locus preventing complexing. Recently, APC has also been shown to be associated with the E-cadherin complex co-precipitating with P-catemnn (Rubinfeld et al., 1993; Su et al., 1993) . Whether the presence of a truncated APC protein in CUBIII impinges upon the integrity of the E-cadherin complex is not known, but it does not account for the lack of m-catemn since this component is present in E-cadherinprecipitable complexes in alternative cell lines known to harbour a truncated APC protein (unpublished observations).
The high incidence of loss of E-cadherin expression in bladder cell lines (33%) correlates well with the in vivo findings (Bringuier et at.. 1993) and provides a valuable tool for the study of cellular and molecular events associated with the disruption of this gene. Whether the findings of a truncated APC protein in one cell line is indicative of its involvement in bladder cancer is unclear but should be viewed in the context of a previous study in which 75% of human colon cell lines displayed a truncated APC product in this assay, contrasting with 40 additional cell lines derived from breast, cervical, pancreatic, lung and prostatic cancer, in which only the full-length APC protein was detected (Smith et al., 1993) . This experimental approach does not account for the possibility of more subtle APC mutations in bladder tumours. but previous results argue that alterations resulting in truncation of the APC protein are not common events associated with the in vitro establishment of human cell lines (Smith et al.. 1993) . To establish this observation as relevant in human bladder cancer, screening of human tumour material will be necessary.
The use of human tumour-derived cell lines from different organs has previously led to the identification of molecular events relevant to specific tumour lesions. In addition, such cell panels have proven useful in the investigation of the role of different tumour-suppressor genes following introduction of either mutant or wild-type elements into cell lines lacking expression of the protein (Takahashi et al., 1991; Goodrich et al., 1992) . There is also considerable evidence that such cell panels retain molecular changes representative of events specific to the organ of interest. An example of this is the finding of the loss of Rb expression in bladder cell lines, which is not found in a similar panel of human colon carcinoma-derived cell lines, consistent with observations recorded in these tumour types in vivo. Tumour suppression following restoration of Rb expression is thus dependent on the recipient cell line used (Bookstein et al., 1990; Takahashi et al.. 1991; Muncaster et al.. 1992 ). This may not be a direct reflection of organ specificity but may possibly be due to background genotypic differences. which may in turn be rooted in organ-specific molecular pathways of neoplastic transformation. If such panels of human cell lines are to continue to be useful in these approaches it is necessary to be aware of multiple genetic parameters which may influence the results recorded. In this study we have demonstrated the limitations in sensitivity of p53 immunostaining when performed in paraffin-embedded sections of bladder tissue and attribute this partly to the specific p53 mutations recorded in bladder tumours. Although alterations associated with the p53 gene continue to be a potentially useful prognostic indicator in bladder cancer, it is clear that immunocytochemistry alone will detect only a proportion of such changes.
The changes recorded within the bladder cell panel used in this study are consistent with events reported in bladder lesions and have proven to be a good indicator of specific genetic changes involved in human bladder cancer. Although it is clear that the frequency of specific changes found in bladder cell lines should not be considered indicative of the frequency of such events in tumours (Cairns et al.. 1994; Spruck et al., 1994) , they nonetheless continue to be useful tools in the study of urothelial neoplastic progression. With the characterisation of additional changes associated with these bladder cell lines we are now better equipped to investigate the functional significance of different genetic changes in urothelial neoplastic progression using this human cell model.
